BRAF and thyroid gland carcinoma: Ultimately, given our increasing understanding of thyroid cancer biology, molecular testing needs to become more precise and directed specifically toward informing what therapy to offer once thyroid cancer is diagnosed, [such as by the identification of actionable RET, NRTK, BRAF, VEGFR mutations, and pathway alterations that would allow for the use of targeted agents (61–64)].